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Abstract: The aim of this study is to describe bilateral optic disc swelling in three consecutive pa-
tients with Blau syndrome or cryopyrin-associated periodic syndrome at a single institution. Case 
1 was a 30-year-old woman receiving 25 mg etanercept twice weekly who had been diagnosed as 
early-onset sarcoidosis by biopsy of skin rashes at 5 months old and genetically diagnosed with 
Blau syndrome with CARD15/NOD2 mutation (N670K) at 13 years old. At 10 years old, she began 
to have uveitis with optic disc swelling in both eyes, resulting in macular degeneration and optic 
disc atrophy at 17 years old only when etanercept was introduced. Case 2 was a 21-year-old man 
receiving adalimumab every 2 weeks who had been diagnosed as early-onset sarcoidosis by biopsy 
of skin rashes at 1.5 years old and genetically diagnosed as Blau syndrome with CARD15/NOD2 
mutation (C495Y) at 5 years old. At 8 years old, around the time of adalimumab introduction, he 
began to show bilateral optic disc swelling which continued until the age of 16 years when the dose 
of adalimumab was increased. Case 3 was a 20-year-old woman receiving canakinumab every 8 
weeks for systemic symptoms such as fever, headache, vomiting, and abdominal pain and later for 
sensorineural hearing disturbance on both sides. She had been diagnosed genetically with cryopy-
rin-associated periodic syndrome with NLRP3 mutation (Y859C) at 7 years old. At 5 years old, she 
was found to have bilateral optic disc swelling, which continued until the age of 10 years when she 
began receiving canakinumab (IL-1β inhibitor). Bilateral optic disc swelling might be tentatively 
designated as a plausible common ocular feature, if it occurred, in autoinflammatory diseases to 
pay more attention to ophthalmic complications in rare diseases. 
Keywords: autoinflammatory diseases; Blau syndrome; Muckle-Wells syndrome; CINCA/NOMID 
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1. Introduction 
Autoinflammatory diseases are a recently established collection of monogenic dis-
eases, which are characterized by abnormal activation of the innate immune system [1–3]. 
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In the entity of autoinflammatory diseases, familial Mediterranean fever is most common 
in the sub-entity of periodic fever diseases, which show remittent fever, skin rashes, and 
joint pain. Cryopyrin-associated periodic syndromes, which have been called cryopy-
rinopathies, follow next at the rate of diseases in the sub-entity of periodic fever diseases. 
The spectrum of cryopyrin-associated periodic syndromes consists of clinical diagnoses 
of familial cold autoinflammatory disease, Muckle–Wells syndrome, and chronic infantile 
neurological cutaneous and articular (CINCA)/neonatal onset multisystem inflammatory 
disease (NOMID) syndrome. The other sub-entities in autoinflammatory diseases are py-
ogenic disorders and granulomatous disorders, including Blau syndrome.  
From the viewpoint of molecular mechanism, defects of interleukin-1β (IL-1β) family 
regulation underlay the pathogenesis of familial Mediterranean fever and cryopyrin-as-
sociated periodic syndromes. More specifically, cryopyrin-associated periodic syndromes 
are caused by gain-of-function mutations in the NLRP3 gene, which lead to overproduc-
tion of a proinflammatory cytokine, IL-1β. Blau syndrome, previously called early-onset 
sarcoidosis, is caused by gain-of-function mutations in the NOD2 gene and characterized 
as a disease linked to nuclear factor-κB (NF-κB) activation, leading to overexpression of 
inflammatory genes, such as tumor necrosis factor-α (TNF-α). Based on the molecular 
pathophysiology, molecular target drugs have now been used to control autoinflamma-
tory diseases [1–3]. 
Most frequent eye manifestations in autoinflammatory diseases may be conjunctivi-
tis [4,5]. In this study, we focused on bilateral optic disc swelling, which happened to be 
shared by three consecutive Japanese patients with Blau syndrome or cryopyrin-associ-
ated periodic syndrome at our single institution. The optic disc swelling in both eyes 
might be a plausible common eye manifestation, if it occurred as a complication, in auto-
inflammatory diseases. In this study, we report the ocular and systemic manifestations in 
these three patients to enhance the understanding of eye complications of the rare diseases 
among pediatricians and ophthalmologists as a subject for further evaluation. 
2. Case Reports 
2.1. Case 1  
A 30-year-old woman with Blau syndrome was systemically stable with oral thalid-
omide 150 mg/day, prednisolone 8 mg/day, tacrolimus hydrate 1 mg/day, loxoprofen 60 
mg/day, methotrexate 8 mg/week, and subcutaneous injection of 25 mg etanercept twice 
weekly. Hypertension was controlled with benidipine (4 mg/day) and imidapril (5 
mg/day). She was short and obese with a height of 131 cm and body weight of 101 kg. 
Genetic testing at the age of 13 years revealed a heterozygous missense mutation in the 
NOD-2 region of the CARD15/NOD2 gene (N670K) [6–10]. Ophthalmologically, the best-
corrected visual acuity was hand movement in the right eye and 0.01 in the left eye. The 
intraocular pressure in both eyes was 10 mmHg. She had intraocular lens implantation in 
both eyes with no aqueous cells and no keratic precipitates. She had optic disc atrophy, 
macular degeneration, and diffuse retinal degeneration of midperipheral fundus in both 
eyes as a sequel to uveoretinitis (Figure 1E–H). She had no intraocular inflammation with 
0.1% betamethasone, four times daily, and 0.1% bromfenac, twice daily. 
In her past history, at the age of 5 months, she began to have papules on the trunk 
(Figure 2C), and then in one month, papules also developed in the upper and lower ex-
tremities on both sides (Figure 2D). She had fever up to 39.8 °C but had no arthropathy at 
that time. Biopsy of the papules revealed non-caseating granuloma with multinucleated 
giant cells (Figure 2A,B) [6]. Blood angiotensin-converting enzyme was elevated to 25.5 
IU/L and lysozyme elevated to 14.3 μg/mL. In 3 months, the papules resolved spontane-
ously to leave mild pigmentation.  




Figure 1. Case 1. Fundus photographs at the age of 17 years (A, right eye; B, left eye), at the age of 18 years (C, right eye; 
D, left eye), and at the age of 30 years (E, right eye; F, left eye). The optic discs in both eyes are hyperemic and blurred at 
17 years (A,B), but become pale tone and atrophic at 30 years with macular degeneration as well as diffuse midperipheral 
retinal degeneration. Optical coherence tomography at 30 years (G, right eye; H left eye) shows the thinned retina at the 
macula in both eyes. 




Figure 2. Case 1. Skin rashes (C,D) and biopsy (A,B) at the age of 5 months. Subcutaneous non-caseating granuloma with 
multinucleated giant cells (arrow in B) and epithelioid cells. Red papules on the back (C) and left foot sole (D). Scale bar 
= 1000 μm in A, 200 μm in B. 
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At 2 years old, she had low-grade fever up to 37.7 °C, bilateral cervical, submandib-
ular, and inguinal small lymphadenopathy, sausage-like swelling of bilateral fingers as 
well as painful arthropathy involving bilateral wrists, knees, ankles, and toes. Plain X-ray 
films revealed no bony destruction in the joints. White blood cell count was 13 × 103/μL, 
C-reactive protein 5.8 mg/dL, and the erythrocyte sedimentation rate was 48 mm/1 h. Eye 
examinations revealed no uveitis. Right inguinal lymph node biopsy showed reactive 
lymphoid hyperplasia. An oral prednisolone dosage of 2 mg/kg body weight resolved 
lymphadenopathy and painful arthropathy within a few days. Oral prednisolone was ta-
pered and discontinued in 2 months. However, oral prednisolone was resumed at the age 
of 3 years. At this time, she received oral prednisolone at 25 mg every other day, and 
began to show small retinal flecks and snowball-like vitreous opacity in the inferior fun-
dus of both eyes. In the following 4 years, she showed stable retinal manifestations with 
retinal periphlebitis and retinal spotty exudates in the inferior fundus of both eyes and 
maintained the visual acuity of 1.2 in both eyes. No corticosteroid eye drops were used 
since she had no anterior chamber inflammation. At the age of 9.5 years, the administra-
tion of oral prednisolone was changed to a daily dose of 17 mg. At 10.5 years old, cyclo-
sporine 40 mg/day was combined with oral prednisolone 10 mg/day. 
At the age of 10 years and 9 months when the dose of oral prednisolone was at 6 mg 
daily in combination with cyclosporine 120 mg/day, she showed 2+ aqueous cells and 1+ 
mutton-fat keratic precipitates in both eyes. The best-corrected visual acuity was 0.6 in the 
right eye and 1.0 in the left eye. The intraocular pressure was 19 mmHg in both eyes. She 
had steroid-induced posterior subcapsular cataract in both eyes and optic disc swelling 
with diffusely edematous retina in the midperipheral fundi of both eyes (Figure 3A,B). 
Fluorescein angiography showed optic disc capillary dilation and leakage with diffuse 
retinal capillary leakage in the midperipheral fundi of both eyes (Figure 3C–H). Topical 
0.1% betamethasone eye drops 4 times daily was started, and oral prednisolone 6 mg daily 
was increased to 30 mg daily in consultation with a pediatrician. In the following 3 
months, the optic disc swelling and aqueous cells subsided and oral prednisolone was 
tapered to 15 mg daily. The best-corrected visual acuity was 1.0 in the right eye and 1.5 in 
the left eye. 
The best-corrected visual acuity in the right eye showed a decrease from 0.7 to 0.1 in 
2 months around 12 years old, and finally to 0.02 in the following 2 months, due mainly 
to the deterioration of cataract. At the age of 12 years and 8 months when oral predniso-
lone was 7 mg daily, she underwent cataract surgery with intraocular lens implantation 
in the right eye, leading to the visual acuity increase from 0.02 to 0.2 in the right eye. At 
13 years old, oral prednisolone was increased to 40 mg daily due to 3+ aqueous cells and 
optic disc swelling in both eyes. The intraocular inflammation subsided, and oral predni-
solone was tapered to 8 mg daily in one year at 14 years old. The visual acuity was 0.1 in 
the right eye and 0.7 in the left eye. At 15 years old, oral cyclosporine was replaced with 
oral tacrolimus 2 mg/day, which was increased to 3 mg/day in 3 months. 
At 16 years old, she began to take oral thalidomide 100 mg/day since she had severe 
systemic arthralgia and persistent uveitis with optic disc swelling in both eyes (Figure 
1A,B). In a month, arthralgia subsided and C-reactive protein returned to the normal level. 
The best-corrected visual acuity was 0.3 in the right eye and 0.2 in the left eye, but de-
creased to 0.1 in the right eye and 0.01 in the left eye in several months. She underwent 
cataract surgery with intraocular lens implantation in the left eye. The best-corrected vis-
ual acuity after the surgery was 0.1 in both eyes. At the age of 17 years and 10 months, she 
began to have subcutaneous injection of etanercept 25 mg twice in a week, and one year 
later, oral methotrexate 8 mg/week was combined to have stable disease thereafter (Figure 
1C,D). The visual acuity, however, gradually decreased to 0.01 in both eyes due to macular 
degeneration and optic disc atrophy in 10 years. 




Figure 3. Case 1. Fundus photographs (A, right eye; B, left eye) showing hyperemic swollen optic discs in both eyes at the 
age of 10 years. Fluorescein angiography in the right eye (C at 22 s, D at 1 min 53 s, E at 5 min 24 s after fluorescein dye 
injection at cubital vein, F, merged) and in the left eye (G at 1 min 5 s, H at 5 min 49 s). 
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2.2. Case 2  
A 21-year-old man with Blau syndrome was systemically stable receiving 200 
mg/day of oral thalidomide, prednisolone (5 mg/day), tacrolimus hydrate (1 mg/day), 
methotrexate (10 mg/week), and subcutaneous injection of 40 mg adalimumab every 2 
weeks. He had a short stature with a height of 129 cm but no obesity with a weight of 35 
kg. Genetic testing at the age of 5 years revealed a heterozygous missense mutation in the 
NOD-2 region of the CARD15/NOD2 gene (C495Y) [7–10]. Ophthalmologically, the best-
corrected visual acuity was 1.2 in the right eye and 0.9 in the left eye. The intraocular 
pressure was 9 mmHg in both eyes. He had intraocular lens implantation in both eyes and 
showed neither aqueous cells nor keratic precipitates in both eyes. The optic discs in both 
eyes were normal and the retina had no abnormalities (Figure 4E–H). Mild posterior cap-
sular opacity (aftercataract) could explain slightly reduced visual acuity in the left eye. He 
used no eye drops because of no intraocular inflammation in both eyes. 
In his past history, at the age of 1.5 years, he developed papules on the trunk (Figure 
5B) and upper limbs, with low-grade fever at 37 °C and bilateral finger swelling. Skin 
biopsy revealed non-caseating granuloma with multinucleated giant cells (Figure 5A,C). 
Eye examinations showed no intraocular inflammation. Arthropathy resolved and C-re-
active protein became undetectable with dosages of oral prednisolone of 9 mg/day and 
cyclosporine of 100 mg/day. At the age of 3 years and 4 months, he began to take 6 
mg/week of oral methotrexate. At 4 years old, he developed bilateral lower lid tumors 
suspected of granuloma, which resolved spontaneously in 4 months.  
At 8 years old, he began to have subcutaneous injection of 20 mg adalimumab every 
2 weeks. At the age of 8.5 years, he continued to show skin eruption, remittent fever, and 
arthropathy of knee, hip, wrist, and finger joints on both sides. At this time for the first 
time, he developed optic disc swelling in both eyes (Figure 4A,B), but he did not show 
afferent pupillary detect or visual acuity decrease in either eye. He began to take oral tha-
lidomide at 75 mg/day, in addition to prednisolone, cyclosporine, and subcutaneous in-
jection of adalimumab. At 16.5 years old, the dose of adalimumab was increased to 40 mg 
every 2 weeks, and around this time, the optic disc swelling in both eyes almost subsided 
(Figure 4C,D). At 19.5 years old, he underwent cataract surgery with intraocular lens im-
plantation in both eyes for steroid-induced cataract. 




Figure 4. Case 2. Fundus photographs (A, right eye; B, left eye) at the age of 8 years showing hyperemic swollen optic 
discs in both eyes. The optic discs in both eyes appear normal at the age of 16 years (C, right eye; D, left eye) and at the 
age of 19 years (E, right eye; F, left eye). Optical coherence tomography shows the normal macula in both eyes (G, right 
eye; H, left eye) at the age of 20 years. 




Figure 5. Case 2. Skin rashes (B) and biopsy (A,C) at the age of 1.5 years. Subcutaneous non-caseating granuloma with 
multinucleated giant cells (arrows in A,C) and epithelioid cells. Red papules on the chest (B). Scale bar = 200 μm in A, 100 
μm in C. 
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2.3. Case 3 
A 20-year-old woman with cryopyrin-associated periodic syndrome was stable with 
a subcutaneous injection of 6 mg/kg body weight of canakinumab every 8 weeks to control 
systemic symptoms such as fever, headache, vomiting, and abdominal pain and also to 
slow down the deterioration of sensorineural hearing disturbance on both sides. Genetic 
testing at the age of 7 years revealed a heterozygous missense mutation in the exon 3 of 
NLRP3 (CIAS1) gene (Y859C) [11]. The best-corrected visual acuity was 1.5 in both eyes, 
and the intraocular pressure was 16 mmHg in both eyes. She had no aqueous inflamma-
tion. The optic discs in both eyes were normal (Figure 6A–D). She had normal height at 
157 cm and weight at 50 kg. 
In her past history, at the age of 4 years, she began to experience vomiting once a 
month, and persistent low-grade fever. She had no myalgia, arthralgia, or skin rashes. Eye 
examinations revealed no optic disc edema in either eye. Serum C-reactive protein was 
elevated to 2–3 mg/dL. She had exudative otitis media on both sides and was treated suc-
cessfully by tympanostomy tubes. At 5 years old, she was found to have optic disc swell-
ing in both eyes (Figure 7A,B) at the consultation of bilateral conjunctival injection. The 
best-corrected visual acuity was 1.0 in both eyes, and she had no inflammation in anterior 
chamber of both eyes. The afferent pupillary detect was not noted in either eye. Head 
magnetic resonance imaging disclosed no intracranial abnormality. 
At 6 years old, she took oral colchicine for fever, for which there was no effect after 
one month. Spinal tap showed protein at 29 mg/dL, glucose at 35 mg/dL, and 44 cells/μL 
of cerebrospinal fluid with 43% of polymorphonuclear cells, indicative of mild aseptic 
meningitis. At 7 years old, she underwent two courses of steroid pulse therapy with 
methylprednisolone for the deterioration of sensorineural hearing disturbance on both 
sides (Figure 8A,B). At 9 years old, she underwent 4 courses of steroid pulse therapy with 
methylprednisolone, but with a limited effect on hearing disturbance in high-pitch sounds 
on both sides (Figure 8C,D). She maintained the visual acuity of 1.2 in both eyes and the 
normal visual field in both eyes by Goldmann perimetric testing, but with persistent bi-
lateral optic disc swelling (Figure 7C,D). 
At the age of 9.5 years, she tried subcutaneous injection of anakinra (IL-1 receptor 
antagonist) every other day for a few months. Around the age of 10 years, she switched 
to have subcutaneous injection of canakinumab (IL-1β inhibitor) at the initial dose of 2 
mg/kg body weight and then at 4 mg/kg body weight (150 mg) every 8 weeks, leading to 
complete resolution of bilateral optic disc swelling (Figure 7E,F). The dose of cana-
kinumab was increased to 6 mg/kg (300 mg) at the age of 15.5 years, leading to better 
preservation of hearing thereafter (Figure 8E). 




Figure 6. Case 3. Fundus photographs (A, right eye; B, left eye) showing normal optic discs and optical coherence tomog-
raphy showing the normal retinal structure of the macula (C, right eye; D, left eye) at the age of 20 years. 




Figure 7. Case 3. Fundus photographs at the age of 5 years (A, right eye; B, left eye), 9 years (C, right eye; D, left eye), and 
12 years (E, right eye; F, left eye). Blurred swollen optic discs in both eyes at the age of 5 years and 9 years have become 
almost normal at the age of 12 years. 




Figure 8. Case 3. Audiograms at the age of 7 years before (A) and after (B) two courses of steroid pulse therapy (arrow). 
Audiograms at the age of 9 years before (C) and after (D) four courses of steroid pulse therapy (arrow). Audiogram at the 
age of 10 years (E) when canakinumab was introduced. 
3. Discussion 
A clinical question in this study was that bilateral optic disc swelling might be a com-
mon eye manifestation, if it occurred, in autoinflammatory diseases. To answer this ques-
tion, we reviewed eye manifestations in three consecutive patients with Blau syndrome 
or cryopyrin-associated periodic syndrome at our single institution. Case 1 with Blau syn-
drome at the age of 6 months had been reported by dermatologists to have granulomatous 
skin lesions by biopsy, leading to the diagnosis of early-onset sarcoidosis [6]. Case 1 and 
Case 2 with Blau syndrome had been reported by pediatricians to take oral thalidomide 
to control systemic symptoms at the age of 16 years and 8 years, respectively [7]. The pre-
sent study focused especially on eye manifestations in Case 1 and Case 2, and described 
their clinical features in response to etanercept and adalimumab introduction, respec-
tively, as current standard therapy, in the disease course after the time points of the pre-
ceding report [7]. The CARD15/NOD2 mutations in Case 1 and Case 2 with minimal clin-
ical data have been reported in multi-center genetic studies of the series of Japanese pa-
tients with Blau syndrome [8–10]. Thus, in this study, the detailed systemic features and 
treatment were shown in parallel with the eye manifestations to understand the relation 
of ocular signs with systemic conditions. 
The NLRP3 mutation in Case 3 with no clinical data had been included in a multi-
center genetic study involving Japanese patients with Muckle–Wells syndrome [11]. No 
detailed description of clinical features in Case 3 were reported so far. From the standpoint 
of clinical symptoms, Case 3 lacked urticaria-like skin rashes and arthralgia, and showed 
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fever, headache, conjunctivitis-like injection, and sensorineural hearing disturbance. The 
clinical diagnosis of Case 3 was located in the spectrum of cryopyrin-associated periodic 
syndromes between Muckle–Wells syndrome and CINCA/NOMID syndrome [12] and 
appeared to be more like Muckle–Wells syndrome. The sensorineural hearing disturbance 
in Case 3 was key for the diagnosis of cryopyrin-associated periodic syndromes (Figure 8). 
The three presented patients, including two with Blau syndrome and one with cry-
opyrin-associated periodic syndrome, showed a common feature of bilateral optic disc 
swelling as an eye manifestation. The two patients with Blau syndrome showed skin 
rashes, remittent fever, and arthralgia and were initially diagnosed as early-onset sar-
coidosis, based on the non-caseating granulomatous lesions in skin biopsy. Of these two 
patients with Blau syndrome, one (Case 1) showed diffuse retinal capillaritis with optic 
disc swelling in both eyes at the age of 10 years (Figure 3A–H), while the other (Case 2) 
showed only the optic disc swelling in both eyes at the age of 8 years (Figure 4A,B). The 
first patient (Case 1) with diffuse retinal capillaritis resulted in diffuse retinal degeneration 
with macular degeneration, leading to poor vision in both eyes. The second patient (Case 2) 
only with bilateral optic disc swelling maintained good visual acuity throughout the 
course after cataract surgery. 
The difference in clinical courses between the two patients (Case 1 and Case 2) with 
Blau syndrome would be attributed to the timing of availability of etanercept and ada-
limumab, TNF-α blockers, in the Japanese market. In Case 1, with poor visual outcome, 
etanercept was introduced at the age of 17 years when she already had macular degener-
ation and optic disc atrophy in both eyes. In contrast, adalimumab was introduced in Case 2 
at the age of 8 years when he developed bilateral optic disc swelling. In Case 3, with cry-
opyrin-associated periodic syndrome, canakinumab, IL-1β inhibitor, was introduced for 
systemic symptoms and sensorineural hearing disturbance at the age of 10 years, and the 
optic disc swelling in both eyes also subsided. Regarding these three patients, afferent 
pupillary defect was not noted in the background of good visual acuity. In Case 1, in the 
later phase with poor visual acuity, the atrophic and rigid iris after uveitis resulted in the 
rigid pupils in both eyes. 
Optic disc swelling is a manifestation of optic papillitis or choked disc caused by 
intracranial hypertension. After intracranial lesions, such as tumors, have been excluded 
by head imaging, the optic disc swelling has to be differentially diagnosed in the list of 
uveitis in children: juvenile idiopathic arthritis (JIA) [13,14], tubulointerstitial nephritis 
and uveitis (TINU) syndrome [15], and bilateral iridocyclitis with retinal capillaritis 
(BIRC) in juvenile [16]. In this way, autoinflammatory diseases such as Blau syndrome 
and periodic fever diseases must be considered in the list of differential diagnoses for 
childhood uveitis. 
In the literature search, bilateral optic disc swelling was indeed described in Blau 
syndrome [17–27], cryopyrin-associated periodic syndromes, including Muckle–Wells 
syndrome and CINCA/NOMID syndrome [28–36], and familial Mediterranean fever 
[37,38]. The optic disc swelling in both eyes in these previous reports appeared to be optic 
papillitis and would not be attributed to intracranial hypertension. Under the circum-
stances, it remains rather strange that most patients, including the present two patients 
(Case 2 and Case 3), maintained good vision even with the optic disc swelling. Optic papil-
litis is usually associated with decreased visual acuity and afferent pupillary defect. This 
discrepancy might be the reason why most case reports used the term ‘optic disc swelling” 
instead of “optic papillitis”. In the present report, Case 2 and Case 3 as well as Case 1 in 
the earlier phase of the disease showed good visual acuity with no afferent pupillary de-
tect in both eyes, and thus, “bilateral optic disc swelling” would be an appropriate term 
to describe the eye manifestation in these patients.  
It remains to be determined whether bilateral optic disc swelling in autoinflamma-
tory diseases would show the response to molecular target drugs as the current standard 
therapy. In the present series of patients, etanercept had an effect on the control of panuve-
itis in both eyes, at least in Case 1 with Blau syndrome. In contrast, the bilateral optic disc 
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swelling as an isolated ocular manifestation in Case 2 and Case 3 might be self-limiting 
since the visual acuity did not decrease and the afferent pupillary defect was not noted. 
The maintenance of good vision in Case 2 and Case 3 might be otherwise ascribed to the 
early introduction of molecular target drugs, adalimumab in Case 2, and canakinumab in 
Case 3, in the earlier course of the diseases. Indeed, the optic disc swelling in Case 2 with 
Blau syndrome was associated with elevated C-reactive protein in blood as a systemic 
inflammatory sign while the optic disc swelling in Case 3 with cryopyrin-associated peri-
odic syndrome would be concurrently related with aseptic meningitis. 
In general, eye manifestations in autoinflammatory diseases are described roughly 
as conjunctivitis, anterior uveitis, and posterior uveitis in the previous reports on the se-
ries of Japanese patients with Blau syndrome [8–10] and Muckle–Wells syndrome [11] 
which also included the present three patients. Optic disc swelling would be the part of 
manifestations in posterior uveitis. Since optic disc swelling might be a vision-threatening 
condition, it is important for pediatricians and ophthalmologists to recognize the mani-
festation as early as possible in the disease course and to start molecular target drugs as 
the current standard therapy. In this context, it would be helpful for clinicians with dif-
ferent specialties to further evaluate that the bilateral optic disc swelling might be a plau-
sible common eye manifestation, if it occurred as a complication of rare diseases, which 
are together listed in the entity of autoinflammatory diseases. 
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